#RemeOs™ #Bioretec #Finland #Tampere #Trauma Screws

Bioretec's CE Mark Approval: A New Era for RemeOs™ Trauma Screws

Bioretec Ltd., a front-runner in absorbable orthopedic implants, has recently achieved a significant milestone with the successful attainment of the CE mark approval for its RemeOs™ Trauma Screw product group. This extensive portfolio encompasses four distinct product lines and boasts over 200 individual products. The CE mark approval opens the door for Bioretec to enhance its presence in the European market, enabling the company to sell its innovative products through the existing distribution networks used for its Activa products.

Expanding Horizons with the CE Mark

The acquisition of the CE mark is a game changer for Bioretec, as it not only facilitates immediate market access across Europe but also positions the company of strong competitor in a market that is already acclimated to absorbable magnesium technology. With the CE mark covering a broad spectrum of indications for both adult and pediatric patients concerning upper and lower extremity treatments, Bioretec is poised to secure a significant market share in Europe. The company's successful experience with absorbable magnesium products in the U.S. also lays a strong groundwork for leveraging the upcoming clinical evidence to broaden its market opportunities.

The RemeOs™ Trauma Screws are crafted from an innovative magnesium alloy, representing a new phase of strong, bioabsorbable materials designed to improve surgical outcomes. These screws integrate traditional surgical techniques with the advantages of absorbable implants, promoting greater efficiency and patient-centric care. As they are absorbed into the body, they support natural bone growth during fracture healing, ultimately eliminating the need for surgical removal and fostering a cost-effective solution aligned with value-based healthcare principles.

Comprehensive Indications and Surgical Versatility

The RemeOs™ product group is constructed to address a variety of surgical needs, featuring products intended for treating epi-/metaphyseal bone fractures and fixation following osteotomies. With indications including the treatment of common fractures in both adults and children, such as ankle and elbow fractures, the screws cater to frequent injuries encountered in medical practice, especially relating to sports and accidents.

Bioretec’s RemeOs™ product lineup comprises four specialized product lines:

• - RemeOs FT: Cannulated headless compression screw
• - RemeOs FC: Partially threaded compression screws with cannulation
• - RemeOs FL: Partially threaded LAG screws with head
• - RemeOs LAG Solid: Non-cannulated LAG screws

These product lines are designed with diameters ranging from 2 mm to 4 mm and lengths from 8 mm to 50 mm, thus accommodating diverse bone sizes. This comprehensive array ensures precision in medical treatment, essential for accurate, tailored surgical intervention in both adult and pediatric surgery.

Facilitating Global Market Expansion

A considerable benefit of the CE mark approval is its international recognition, facilitating product registration in numerous countries. This global perspective is critical as Bioretec aims to build its presence in about 40 countries around the world. The availability of RemeOs products under the CE mark invites additional local registrations, thus simplifying the process of market entry.

The CE mark effectively enhances Bioretec's capacity to collect real-world evidence and post-market clinical data from reputable institutions throughout Europe. This valuable data not only aids in enhancing credibility but also supports the advancement of regulatory registrations in the U.S., aligning with the company’s objective of broadening its indication spectrum domestically.

Market Opportunity and Future Outlook

The market opportunity in orthopedic trauma solutions is colossal, valued at approximately $9.0 billion globally in 2024. The increasing prevalence of musculoskeletal disorders, driven by demographics and sports-related injuries, amplifies the need for effective treatment solutions. As the population ages, the demand for innovative orthopedic products continues to rise, emphasizing value-based healthcare that prioritizes patient outcomes.

With minimal invasive surgical practices gaining momentum and the need for technological advancements, Bioretec's RemeOs™ product line is optimally situated to meet growing market demands. The potential for innovation in absorbable orthopedic implants aligns seamlessly with current healthcare trends, suggesting a promising future for Bioretec in dominating both the European and potentially global markets.

Final Thoughts on RemeOs' Impact

With the recent CE mark approval, Bioretec stands at the threshold of transformational growth. The company, led by CEO Alan Donze, acknowledges this exceptional achievement as more than just a regulatory accomplishment; it signifies a pathway to revolutionize fracture treatment standards and improve patient care worldwide. The upcoming stages of product registration and clinical validation will undoubtedly shape the future trajectory of Bioretec and solidify its position as a leader in orthopedic innovation.

In summary, Bioretec’s commitment to developing specialized fixation solutions is a testament to its dedication to enhancing the quality of life for patients suffering from bone injuries. The successful introduction of the RemeOs™ trauma screws strengthens the company’s foundation for broadening its impact globally, ultimately aiming to redefine standards in orthopedic treatment.

For further inquiries, please contact:

• - Alan Donze, CEO: +1 619 977 5285
• - Johanna Salko, CFO: +358 40 754 8172

Visit Bioretec for more information on their innovative product offerings.